Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 11: Antibody-drug conjugates
Submit an article Journal homepage
1,207
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Antibody-drug conjugates in oncology: insights into Current challenges

Ahmad Z. Al Meslamania College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates;b AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab EmiratesCorrespondence[email protected]
View further author information
&
Mohammad F. Bostanudina College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates;b AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab EmiratesView further author information
Pages 1035-1038 | Received 19 Oct 2023, Accepted 24 Oct 2023, Published online: 30 Oct 2023

References

  • Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet (London, England). 2019;394:793–804. doi: 10.1016/S0140-6736(19)31774-X
  • Matsuda Y, Mendelsohn BA. An overview of process development for Antibody-drug conjugates produced by chemical conjugation technology. Expert Opin Biol Ther. 2021;21:963–975. doi: 10.1080/14712598.2021.1846714
  • Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35. doi: 10.1042/BSR20150089
  • Nicolò E, Giugliano F, Ascione L, et al. Combining Antibody-drug conjugates with immunotherapy in solid tumors: Current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395. doi: 10.1016/j.ctrv.2022.102395
  • Wu Y, Fang Y, Wei Q, et al. Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proc Natl Acad Sci. 2022;119:e2214278119. doi: 10.1073/pnas.2214278119
  • Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20. doi: 10.1056/NEJMoa2203690
  • Andrikopoulou A, Zografos E, Liontos M, et al. Trastuzumab Deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clin Breast Cancer. 2021;21:e212–e219. doi: 10.1016/j.clbc.2020.08.006
  • Lee J, Park YH. Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer. Future Oncol. 2022;18:7–19. doi: 10.2217/fon-2021-0550
  • Abelman RO, Spring L, Fell GG, et al. Sequential use of Antibody-drug conjugate after Antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. J Clin Oncol. 2023;41:1022. doi: 10.1200/JCO.2023.41.16_suppl.1022
  • Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and Strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713. doi: 10.3390/cancers15030713
  • Kostova V, Désos P, Starck J-B, et al. The chemistry behind ADCs. Pharmaceuticals (Basel). 2021;14(5):442. doi: 10.3390/ph14050442
  • Marei HE, Cenciarelli C, Hasan A. Potential of Antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22:255. doi: 10.1186/s12935-022-02679-8
  • D’Arienzo A, Verrazzo A, Pagliuca M, et al. Toxicity profile of Antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113. doi: 10.1016/j.eclinm.2023.102113
  • Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of Antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–344. doi: 10.1038/s41571-021-00470-8
  • Trail PA, Willner D, Lasch SJ, et al. Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates. Science. 1993;261:212–215. doi: 10.1126/science.8327892
  • Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1/Programmed death Ligand 1 therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2592–2600. doi: 10.1200/JCO.19.01140
  • Takegawa N, Nonagase Y, Yonesaka K, et al. DS‐8201a, a New HER2‐targeting Antibody–drug conjugate Incorporating a Novel DNA Topoisomerase I Inhibitor, Overcomes HER2‐positive Gastric cancer T‐DM1 resistance. Int J Cancer. 2017;141(8):1682–1689. doi: 10.1002/ijc.30870
  • Li JY, Perry SR, Muniz-Medina V, et al. A Biparatopic HER2-targeting Antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117–129. doi: 10.1016/j.ccell.2015.12.008
  • Hosseinzadeh A, Merikhian P, Naseri N, et al. MUC1 is a potential target to overcome Trastuzumab resistance in breast cancer therapy. Cancer Cell Int. 2022;22:110. doi: 10.1186/s12935-022-02523-z
  • Schwarz LJ, Hutchinson KE, Rexer BN, et al. An ERBB1-3 neutralizing Antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression. JNCI J Natl Cancer Inst. 2017;109(11):djx065. doi: 10.1093/jnci/djx065
  • Damelin M, Zhong W, Myers J, et al. Evolving Strategies for Target Selection for Antibody-Drug Conjugates. Pharm Res. 2015;32(11):3494–3507. doi: 10.1007/s11095-015-1624-3
  • Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug Conjugates Designed to Eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–3221. doi: 10.1158/0008-5472.CAN-05-3973
  • Chari RVJ, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew Chemie Int Ed. 2014;53:3796–3827. doi: 10.1002/anie.201307628
  • Kovtun YV, Goldmacher VS. Cell Killing by Antibody–Drug Conjugates. Cancer Lett. 2007;255(2):232–240. doi: 10.1016/j.canlet.2007.04.010

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.